Search results
Results from the WOW.Com Content Network
The US Food and Drug Administration has approved the first medication for a common form of liver inflammation called nonalcoholic steatohepatitis, or NASH, the agency said Thursday.
NASH was first described in 1980 in a series of patients of the Mayo Clinic. [7] Its relevance and high prevalence were recognized mainly in the 1990s. Some think NASH is a diagnosis of exclusion, and many cases may in fact be due to other causes. [8]
In the study Children of the 90s, 2.5% born in 1991 and 1992 were found by ultrasound at the age of 18 to have non-alcoholic fatty liver disease; five years later transient elastography found over 20% to have the fatty deposits on the liver, indicating non-alcoholic fatty liver disease; half of those were classified as severe. The scans also ...
By Leroy Leo and Mariam Sunny (Reuters) -The U.S. FDA has approved Madrigal Pharmaceuticals' drug for a fatty liver disease known as non-alcoholic steatohepatitis (NASH), the first treatment to ...
The name "non-alcoholic steatohepatitis" (NASH) was later defined in 1980 by Jurgen Ludwig and his colleagues from the Mayo Clinic [146] to raise awareness of the existence of this pathology, as similar reports previously were dismissed as "patients' lies". [142]
For premium support please call: 800-290-4726 more ways to reach us
Resmetirom, sold under the brand name Rezdiffra, is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis. [1] It is a thyroid hormone receptor beta (NR1A2) agonist. [1] The most common side effects include diarrhea and nausea. [2] Resmetirom was approved for medical use in the United States in March 2024.
Aramchol is an investigational drug being developed by Galmed Pharmaceuticals as a first-in-class, potentially disease modifying treatment for nonalcoholic steatohepatitis, or NASH, a more advanced condition of non-alcoholic fatty liver disease. [1] [2] [3] [4]